U.K. drug maker GlaxoSmithKline said Monday it had secured its takeover of Rockville-based Human Genome Sciences after agreeing to pay a higher price for the U.S. biotechnology company.
In a joint announcement by the two companies, GSK said it would pay $14.25 per share for Human Genome Sciences, up from its previous offer of $13 per share. The offer values Human Genome Sciences at $3.6 billion.